Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Gross Margin (2020 - 2025)

Abeona Therapeutics has reported Gross Margin over the past 8 years, most recently at 80.74% for Q4 2025.

  • Quarterly results put Gross Margin at 80.74% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 71.96% (changed N/A YoY), and the annual figure for FY2025 was 73.68%, changed.
  • Gross Margin for Q4 2025 was 80.74% at Abeona Therapeutics, up from 75.0% in the prior quarter.
  • Over the last five years, Gross Margin for ABEO hit a ceiling of 80.74% in Q4 2025 and a floor of 47.06% in Q4 2022.
  • Median Gross Margin over the past 3 years was 65.0% (2022), compared with a mean of 45.74%.
  • Peak annual rise in Gross Margin hit -1000bps in 2023, while the deepest fall reached -1000bps in 2023.
  • Abeona Therapeutics' Gross Margin stood at 47.06% in 2022, then skyrocketed by 217bps to 55.0% in 2023, then skyrocketed by 47bps to 80.74% in 2025.
  • The last three reported values for Gross Margin were 80.74% (Q4 2025), 75.0% (Q2 2025), and 55.0% (Q2 2023) per Business Quant data.